- ASSOCIATE PROFESSOR Medicine, Liver Diseases
American Board of Internal Medicine
MD, New York Presbyterian - Weill Cornell Medical Center
A.B., Harvard University
M.D., Cornell University Medical College
The New York Hospital-Cornell Medical Center
Residency, Internal Medicine
New York Presbyterian - Weill Cornell Medical Center
Hospital of the University of Penn.
- Dr. Bansal joined the faculty at Mount Sinai in 2001 after completing Gastroenterology Fellowship at the University of Pennsylvania. In 2002 she became the Hepatology Fellowship Director, leading one of the largest hepatology fellowships in the United States. While remaining clinically active, she has also developed an NIH-funded basic research program focusing on understanding underlying molecular mechanisms of liver fibrosis/cirrhosis in an effort to develop novel anti-fibrotic therapies. Her research interests focus on the role of Matrix Metalloproteinase-2 in liver fibrosis and regeneration and Role of the chemokine receptors, CXCR4 and CCR5, on stellate cell biology and fibrogenesis. The latter has great implications in understanding mechanism of HCV- and HIV/HCV-induced liver disease. Her research has resulted in numerous awards which include the AGA Shirley and Miles Fiterman Basic Research Prize(2005), The Dr. Harold and Golden Lamport Research Award (2006), and the Regal Award for Research Excellence in GI and Liver(2006).
Miles and Shirley Fiterman Basic Research Award
American Gastroenterological Association
Dr. Harold and Golden Lamport Research Award
Regal Awards: Research Excellence in GI and Liver
Komarov Competition-Basic Science. Philadelphia, Pennsylvania
C. Richard Bowman Memorial Award
The New York Hospital-Cornell University Medical College
David E. Rogers Memorial Prize
The New York Hospital-Cornell University Medical College
ResearchSpecific Clinical/Research Interests: Role of chemokine receptors, CXCR4 and CCR5, on stellate cell biology and fibrogenesis; molecular regulation of hepatic fibrosis and regeneration
Current Students: Yedidya Saiman
Postdoctoral Fellows: Ana Tuyama; Ritu Agarwal
Research Personnel: Feng Hong
Summary of Research Studies:
Brief Biosketch and Research Interests Dr. Bansal joined the faculty at Mount Sinai in 2001 after completing Gastroenterology Fellowship at the University of Pennsylvania. In 2002 she became the Hepatology Fellowship Director, leading one of the largest hepatology fellowships in the United States. While remaining clinically active, she has also developed an NIH-funded basic research program focusing on understanding underlying molecular mechanisms of liver fibrosis/cirrhosis in an effort to develop novel anti-fibrotic therapies. Her research interests focus on the role of Matrix Metalloproteinase-2 in liver fibrosis and regeneration and Role of the chemokine receptors, CXCR4 and CCR5, on stellate cell biology and fibrogenesis. The latter has great implications in understanding mechanism of HCV- and HIV/HCV-induced liver disease.
Bansal MB, Friedman SL. Reversal of Hepatic Fibrosis-Fact or Fantasy?. Hepatology 2006; 43: S82-88.
Kodali R, Hajjou M, Berman AB, Schecter AD, Zhang S, Pan JJ, Bansal MB. Chemokines Induce Matrix Metalloproteinase-2 Through Activation of Epidermal Growth Factor Receptor in Arterial Smooth Muscle Cells. Cardiovascular Research 2006; 69: 706-715.
Bansal MB, Kovalovich K, Li W, Gupta R, Taub RA, Alvarez CE, Safadi R, Radbill B, Friedman SL, Agarwarl A. Interleukin-6 Protects Hepatocytes from CCl4- Mediated Necrosis and Apoptosis in Mice by Reducing MMP-2 Expression. Journal of Hepatology 2005; 42: 548-556.
Safadi R, Ohta M, Alvarez CE, Friedman SL, Bansal MB, Mehal WZ, Fiel MI. Immune Stimulation of Hepatic Fibrogenesis by CD8 Lymphocytes and its Attenuation by Transgenic Interleukin 10 from Hepatocytes. Gastroenterology 2004; 127: 870-882.
Friedman SL, Bansal MB. The enlarging role of matrix metalloproteinases in liver injury - beyond scar degradation. J Hepatol 2002 Aug; 37(2): 293-294.
Friedman SL, Bansal MB, editors. Fibrogenesis. San Diego, Elsevier,Academic Press; pp34-38.
Hong F MD, Tuyama A, Agarwal R, Gupta R, Cheng X, Garg A, Inoue YM, Fiel M MD, Schwartz M MD, Schwartzkopf M, Schecter AD, Bansal MB MD. Hepatic Stellate Cells Express Functional CXCR4: Role in Stromal Cell Derived Facter -1a medicated Stellate Cell Activation. Hepatology 2009; 49: 2005-2067.
Tuyama AC, Hong F MD, Saiman Y, Wang C MD, Mosoian A, Chen P, Chen BK, Klotman M MD, Bansal MB MD. HIV-1 Infects Human Hepatic Stellate Cells and Promotes Collagen I and MCP-1 Expression: Implications for hepatic fibrosis in HIV/HCV co infection. Hepatology 2010; 52: 612-621.
Radbill B MD, Gupta R, Ramirez MM, DiFeo A, Martignetti J, Alvarez C MD, Friedman SL MD, Narla G MD, Vrabie R, Saiman Y, Bowles R, MB Bansal. Loss of Matrix Metalloproteinase-2 Amplifies Murine Toxin INduced Liver Fibrosis by Upregulating Collagen I Expression. Digestive Diseases and Sciences 2011; 56: 406-416.
Bansal MB MD, Friedman SL MD. Hepatic Fibrogenesis. In: Sherlock's Diseases of the Liver and Biliary System. pp94-101.
Bansal MB MD, Blackard J. Effect of HIV on Liver Cell Populations. In: HIV and Liver Diseases. Springer;.
- A Phase 3, Global, Multicenter, Randomized, Open-Label Study to Investigate the Safety and Efficacy of Sofosbuvir/Velpatasvir/GS-9857 Fixed-Dose Combination for 12 Weeks and Sofosbuvir/Velpatasvir for 12 Weeks in Direct-Acting Antiviral-Experienced Subjects with Chronic HCV Infection who Have Not Received an NS5A Inhibitor
- Efficacy and Safety Study of Cenicriviroc for the Treatment of Nonalcoholic Steatohepatitis (NASH) in Adult Subjects with Liver Fibrosis (CENTAUR)
- A Phase 3, Global, Multicenter, Randomized, Open-Label Study to Investigate the Safety and Efficacy of Sofosbuvir/Velpatasvir/GS-9857 Fixed-Dose Combination for 8 Weeks and Sofosbuvir/Velpatasvir for 12 Weeks in Subjects with Chronic Genotype 3 HCV Infection and Cirrhosis
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Dr. Bansal did not report having any of the following types of financial relationships with industry during 2015 and/or 2016: consulting, scientific advisory board, industry-sponsored lectures, service on Board of Directors, participation on industry-sponsored committees, equity ownership valued at greater than 5% of a publicly traded company or any value in a privately held company. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.
Physicians who provide services at hospitals and facilities in the Mount Sinai Health System might not participate in the same health plans as those Mount Sinai hospitals and facilities (even if the physicians are employed or contracted by those hospitals or facilities).
Information regarding insurance participation and billing by this physician may be found on this page, and can also be obtained by contacting this provider directly. Because physicians insurance participation can change, the insurance information on this page may not always be up-to-date. Please contact this physician directly to obtain the most up-to-date insurance information.
Insurance and health plan networks that the various Mount Sinai Health System hospitals and facilities participate in can be found on the Mount Sinai Health System website.
Icahn (East) Building Floor 11th Floor Room Room 11-70E
1425 Madison Avenue
New York, NY 10029
17 E 102nd Street
New York, NY 10029
- Medicaid of New York